Your browser doesn't support javascript.
Polycythemia in a Pediatric Patient with Chronic Kidney Disease: Overuse of Erythropoetin During COVID-19 Isolation
Turkish Journal of Pediatric Disease ; 15(5):434-436, 2021.
Article in English | EMBASE | ID: covidwho-2231627
ABSTRACT
We describe a case of a patient with Chronic Kidney Disease who developed polycythemia due to Erythropoiesis Stimulating Agents overuse during COVID-19 isolation. A 12-year-old male had not been able to attend routine controls since had been in isolation for 4 months after the COVID-19 outbreak. He had continued to take Erythropoiesis-Stimulating Agents during that period at the starting dose of 150 U/kg/week. He had been on peritoneal dialysis in the last year because of end-stage renal failure. Laboratory investigation revealed a hemoglobin (Hb) level of 20.8 g/dl, hematocrit level of 66%, creatinine level of 6.5 mgr/dl. He underwent daily phlebotomy sessions (10cc/kg/session). During this period aspirin was also started (5mg/kg). After 5 sessions his Hb level decreased to 14 gr/dl and hematocrit to 40%. Pediatric nephrologist should be aware that there is a potential risk of polycythemia with Erythropoiesis Stimulating Agents when Hb level is not appropriately followed on a routine basis. Copyright © 2021 Ankara Pediatric Hematology Oncology Training and Research Hospital. All rights reserved.
Keywords

Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Observational study / Prognostic study Language: English Journal: Turkish Journal of Pediatric Disease Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Observational study / Prognostic study Language: English Journal: Turkish Journal of Pediatric Disease Year: 2021 Document Type: Article